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Summary
Quantitative procedures for evaluating added values from new markers over a conventional
risk scoring system for predicting event rates at specific time points have been extensively stud-
ied. However, a single summary statistic, for example, the area under the receiver operating
characteristic curve or its derivatives, may not provide a clear picture about the relationship be-
tween the conventional and the new risk scoring systems. When there are no censored event time
observations in the data, two simple scatterplots with individual conventional and new scores for
“cases” and “controls” provide valuable information regarding the overall and the subject-specific
level incremental values from the new markers. Unfortunately, in the presence of censoring, it
is not clear how to construct such plots. In this paper, we propose a nonparametric estima-
tion procedure for the distributions of the differences between two risk scores conditional on the
conventional score. The resulting quantile curves of these differences over the subject-specific
conventional score provide extra information about the overall added value from the new marker.
They also help us to identify a subgroup of future subjects who need the new predictors, espe-
cially when there is no unified utility function available for cost-risk-benefit decision making.
The procedure is illustrated with two data sets. The first is from a well-known Mayo Clinic PBC
liver study. The second is from a recent breast cancer study on evaluating the added value from
a gene score, which is relatively expensive to measure compared with the routinely used clinical
biomarkers for predicting the patient’s survival after surgery.
Keywords: Discriminant analysis; Nonparametric function estimation; Prediction; Receiver
operating characteristic curve.
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1. INTRODUCTION
For a binary phenotypic outcome, numerical and graphical methods for evaluating an overall
incremental value from a new set of markers over a conventional risk scoring system have been
extensively studied (Bamber, 1975; Zhou et al., 2002; Pepe, 2003; Pepe et al., 2004; Greenland
& O’Malley, 2005; Ware, 2006; Pencina et al., 2008). Novel generalizations of these procedures
to handle censored event time data have also been proposed (Hanley & McNeil, 1982; Harrell
et al., 1996; D’Agostino et al., 1997; Pencina & D’Agostino, 2004; Heagerty and Zheng, 2005;
Cook et al., 2006; Cai and Cheng, 2008; Uno et al, 2009). Evaluating the added value from
the new markers with an overall summary measure is an important first step for establishing
a prediction rule. On the other hand, even when the new markers have either an impressive
or no meaningful overall incremental value, the next critical step is to identify patients who
would or would not need the additional markers for better prediction via their conventional risk
scores. Unfortunately, relatively little effort has been made for establishing a systematic, analytic
procedure for such “subgroup analysis” in the statistical or medical literature (D’Agostino, 2006).
Recently, Tian et al. (2009) proposed a procedure for this type of subject-specific level analysis
by controlling a pre-specified simultaneous inference error rate. However, their proposal does
not incorporate censoring and depends heavily on the choice of the utility function, a weighted
average between the false positive and negative rates.
For binary outcomes, simple scatterplots of individual conventional risk scores vs. new ones
provide valuable information about an overall and also personalized-level incremental values of
the new markers (Gu & Pepe, 2009). For example, in selecting patients with advanced or end-
stage primary biliary cirrhosis, PBC, for orthotopic liver transplantation, five patients’ baseline
covariates, namely age, albumin, bilirubin, edema and prothrombin time, were identified to be
important predictors for the patient’s survival based the data from a Mayo Clinic study (Dickson
et al., 1989; Fleming and Harrington, 1991, pp. 160). Suppose that we would like to know the
added value from the bilirubin measure over the other four variables with respect to prediction
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of 5-year survival based on observations from 416 patients with complete information on those
predictors. To this end, we first obtain a risk score based on these four variables without bilirubin,
0.29  (age/10) 3.49  log (albumin)  1.33  edema  3.07  log (prothrombin time), p1.1q
by fitting the data with a simple additive Cox model using partial likelihood estimation procedure
(Cox, 1972). Based on (1.1) and the standard Breslow estimator for the baseline cumulative
hazard, we obtain individual patients’ 5-year cumulative mortality risk, denoted by p1i, i 
1,    , 416. Next, we fit the data using another additive Cox model with all five covariates
including bilirubin. The resulting risk score is
0.40  (age/10) 2.51  log (albumin)  0.86  log (bilirubin) 
0.90  edema  2.4  log (prothrombin time). p1.2q
Let p2i denote the ith individual five-year mortality rate based on (1.2).
In the PBC dataset, there are 196 censored survival observations by Year 5 and 114 patients
died during this time period. Figure 1(a) shows the scatterplot of p1i vs. the difference pp2ip1iq
for those 114 observable “cases.” The majority of those black dots in the figure are above the
horizontal line, indicating that globally the bilirubin provides extra information about the 5-
year mortality rate for those “cases.” Moreover, for a subject with p1 between 0.2 and 0.6, the
corresponding p2 tends to be substantially higher. Figure 1(b) shows the scatterplot for the
observable “controls,” who survived and were still under follow-up by Year 5. Here, most of p2
tend to be smaller than their p1, indicating that bilirubin has an overall incremental value. At
the personalized level, it appears that for the survived patients whose conventional risk scores
are between 0.15 and 0.35, bilirubin provides nontrivial improvement for predicting survival
beyond 5 years. If there were no censored observations in the data, the scatterplots in Figure
1, coupled with the standard lowess curves for the scatter diagram (dark curves), would provide
a valuable tool for quantifying global and subject-specific level performance using Model (1.2)
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with bilirubin. Unfortunately, for the present example, the number of censored observations is
substantial and it is not clear how to construct valid plots like Figure 1.
In this paper, with censored survival data we propose a nonparametric procedure to consis-
tently estimate quantiles of the distributions of the difference pp2  p1q given p1 for cases and
controls. The resulting quantile curves are then presented using a similar configuration to Figure
1. The new method is derived under a more general setting. Here, a case is defined as the
survival time being in a time interval I1, while a control is defined as the survival time in an
interval I0, where I1 is entirely on the left hand side of I0. By repeating the analysis with various
pairs of I0 and I1, one may find, for example, that the new predictors are not useful when these
two intervals are widely separated (for instance, short- vs. long-term survival), but may have
substantial incremental values when these two intervals are relatively close. This type of finding
can be quite informative for cost-benefit decision making. The new procedure is illustrated with
the above Mayo Clinic data and also with the data set from a breast cancer study to evaluate
the additional prediction ability based on a new gene risk score on top of conventional clinical
markers. The second example is particularly interesting due to the fact that it is relatively ex-
pensive to measure the gene score compared with clinical markers, which are routinely obtained
after patients’ surgery for breast cancer.
2. ESTIMATING THE DISTRIBUTION OF THE NEW RISK SCORE
CONDITIONAL ON THE OLD RISK SCORE
Let T be the time to an event of interest and Z be its corresponding vector of baseline
covariates. For the two specific time intervals I1 P rt1, t2q and I0 P rt3, t4q discussed in Section 1,
suppose that for a given Z we are interested in estimating the risk of a case:
prpT P I1 | Zq{tprpT P I0 | Zq   prpT P I1 | Zqu. p2.1q
Let U and V be two vectors, which are functions of Z. Here, U is a function of conventional
markers only, but V is a function of both conventional and new predictors. One of the questions
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is how to identify patients with U, who may need V for better prediction of (2.1). This is a
particularly important question when it is costly or invasive to measure the new markers. Often,
the event time T may be censored by a censoring variable C. Assume that C is independent of
T and Z. Let Gpq be the survival function of C. Moreover, let the binary variable E  0, if
T P I0;  1, if T P I1. Note that one can assign an arbitrary value (other than 0 or 1) for E
when T is outside of these two time intervals. Now, let tpTi, Ci, Ei, Zi, Ui, Viq , i  1, . . . , nu be
n independent copies of pT,C,E, Z, U, V q . For Ti, we observe tXi,∆iu, where Xi  min pTi, Ciq,
and ∆i  1, if Xi  Ti, and 0, otherwise, i  1,    , n. Due to potential censoring, the binary
variable E may not be observable.
To construct a risk score system with U, let us consider the standard Cox proportional hazards
model with the risk score β1U, where β is an unknown vector of regression parameters. With the
above observed data, let βˆ be the maximum partial likelihood estimator for β. In practice, this
semi-parametric model is simply an approximation of the “true” model. Under a mild condition,
βˆ converges to a constant, as nÑ 8 (Hjort,1992), regardless of the adequacy of the Cox model.
This property is critical for developing our new procedure. Similarly, for V, we fit the data with
another additive Cox’s model with the risk score γ1V. Let γˆ be the corresponding estimator for
γ.
Now, consider an independent future subject from the same study population whose
pT,E, Z, U, V q  pT 0, E0, Z0, U0, V 0q. To estimate (2.1) with U0, let pˆ1pU0q be the estimator for
(2.1) constructed from the Breslow estimator for the underlying cumulative hazard function of
the above Cox’s model and βˆ1U0. Explicitly, letting Λˆ1pq denote the Breslow estimator, then
pˆ1pU
0q is
exptΛˆ1pt1qe
pβ1U0u  exptΛˆ1pt2qe
pβ1U0u
exptΛˆ1pt1qe
pβ1U0u  exptΛˆ1pt2qe
pβ1U0qu   exptΛˆ1pt3qe
pβ1U0u  exptΛˆ1pt4qe
pβ1U0qu
.
Similarly, let pˆ2pV 0q be the corresponding estimator via the covariate vector V 0. To compare
these two predictors, let DˆpZ0q  pˆ2pV 0q  pˆ1pU0q. Note that to make overall comparisons
between models with U and V , one may estimate the distribution of DˆpZ0q given E0  e, where
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e is either 0 or 1. If V has an overall added value over U, one would expect that for e  1, that
is, for those future subjects with T 0 P I1, DˆpZ0q has more positive mass, and if e  0, DˆpZ0q
has more negative mass. Recently various analytic methods based on the distributions of DˆpZ0q
for cases and controls were proposed, for example, by Pencina et al. (2008), Gu & Pepe (2009)
and Uno et al. (2009) to summarize the overall incremental value of the new markers.
In this paper, we are also interested in the subject-specific level evaluation for the incremental
values, that is, estimating the distribution of DˆpZ0q conditional on E0  e and pˆ1pU0q  p,
where e is either 0 or 1, and p belongs to J  rl, rs is a strictly inner subset of the support of
pˆ1pU
0q. Let qτeppq be the τth conditional quantile of the above distribution, for 0   τ   1. To
estimate qτeppq, we utilize a nonparametric quantile regression estimation technique by letting
the quantile of pˆ2pV 0q be locally linear in pˆ1pU0q (Yu & Jones, 1998). Specifically, without
censored observations, for any given p, we minimize the following objective function with respect
to a and b,
n¸
i1
IpEi  eqKh tψppˆ1pUiqq  ψppqu ρτ pψppˆ2pViqq  a brψtpˆ1pUiqu  ψppqsq, p2.2q
where Khpxq  Kpx{hq{h, Kpq is a symmetric probability density function, h is a bandwidth
such that h  Opnνq with ν P p1{2, 1{5s and ρτ pxq is the check function, which is τx if x ¥ 0,
and is pτ  1qx if x   0. Here, we choose a proper transformation ψtpˆ1pUqu of pˆ1pUq to improve
smoothing, where ψpq : p0, 1q Ñ p8,8q is a known, non-decreasing function (Wand et al.,
1991; Park et al., 1997). For example, one may let ψppq  log t log p1  pqu . Let the minimizer
of (2.2) be aˆ and bˆ. Then let
qˆτeppq  ψ
1 paˆq  p p2.3q
be an estimator for qτeppq.
Since E may not be observable in (2.2), we replace IpE  eq by IpE:  eq, with an inverse
probability weighting technique, where E: is 1 if X P I1; 0 if X P I0. Specifically, let Gˆpq denote
the Kaplan Meier estimator of Gpq and let η be a pre-specified time point such that Gpηq ¡ 0.
The choice of the weight depends of the choice of I1 and I0. For the case where I0 is an interval
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such that t4   η, the weight pwi  ∆i{GˆpXiq for both IpE:i  1q and IpE:i  0q. This may be
justified heuristically using the argument that Et pwiIpE:i  eq | Zi, Tiu  EtIpE  eq | Zu. For
the case when t3   η, and t4  8 for the interval I0, the weights pwi  ∆i{GˆpXiq and pwi  1{Gˆpt3q
are used for IpE:i  1q and IpE
:
i  0q, respectively. Heuristically this can be justified with the
argument that Et pwiIpE:i  0q | Zi, Tiu  EtIpE  0q | Zu. This inverse probability weighting
adjustment, coupled with (2.2), results in the following minimand:
n¸
i1
pwiIpE:i  eqKh tψtpˆ1pUiqu  ψppqu ρτ pψtpˆ2pViqu  a brψtpˆ1pUiqu  ψppqsq. p2.4q
Then, the corresponding estimator qˆτeppq for qτeppq is given by (2.3), but with aˆ being a minimizer
of (2.4) with respect to a and b. In the Appendix, we show that for each fixed τ, suppPJ |qˆτeppq
qτeppq| Ñ 0, in probability as nÑ 8.
In practice, it is important to know how to choose the smooth parameter h in the above
nonparametric estimation. To this end, we consider a commonly used K-fold cross-validation
procedure. Specifically, we randomly partition the data into K disjoint parts, I1,    , IK . For
each k, we use the data not in Ik to obtain the regression parameter estimators in the above two
Cox’s models, denoted by βˆpkq and γˆpkq. Moreover, let tpˆ1pkqpq, pˆ2pkqpq, qˆτepkqpqu denote the
respective estimators corresponding to tpˆ1pq, pˆ2pq, qˆτepqu based on data not in Ik. We propose
to choose h by minimizing
K¸
k1
¸
iPIk
pwiIpE:i  eqItpˆ1pkqpUiq P J uρτ  ψ  pˆ2pkqpViq( ψ qˆτepkqtpˆ1pkqpUiqu pˆ1pkqpUiq .
p2.5q
In practice, the lower and upper bounds of J may be chosen as, for example, the 3rd and 97th
percentiles of the empirical distribution of pˆ1pU0q.
3. EXAMPLES
First, let us revisit the PBC example discussed in the Introduction Section. Figure 2 gives
the Kaplan-Meier estimate with the survival times from 416 patients. Assume that we are
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interested in two time intervals, I0  p5,8q(years) and I1  r0, 5s (years). On average the 5-year
cumulative mortality rate is about 0.3. Here, pˆ1pUiq is obtained without using bilirubin and
pˆ2pViq is with bilirubin, i  1,    , n, via the risk scores (1.1) and (1.2) and two working Cox’s
models. To estimate qτepq, we let ψ in (2.4) be the logp logq function and the kernel function
be the standard normal density function. To choose the smooth parameter h, we used 10-fold
cross validation scheme with (2.5). For instance, to estimate the median q0.5epq for patients
who would die by Year 5, the resulting “optimal” h with respect to ψ-scale is 1.6. The interval
J over which we construct the median curves is p0.10, 0.995q. Figure 3(a) gives the estimated
median curve of Dˆ over the risk score pˆ1 (solid curve). The lower and upper boundaries of the
shaded area are the corresponding 25th and 75th percentile curves. Figure 3(b) gives the plots
which are the counterparts for subjects who would survive more than 5 years. In Figure 3(c),
we provide the density function estimate of pˆ1 score. The majority of patients whose risk scores
without using bilirubin are between 0.1 and 0.6. Based on Figure 3, the distributions of Dˆ for
“cases” over the interval p0.1, 0.995q have more positive mass, especially for pˆ1 between 0.2 and
0.6. The bilirubin helps greatly for the “controls” when pˆ1 is between 0.2 and 0.6, that is, the
false positive rate can be drastically reduced with bilirubin. We have also examined extensively
the added values of bilirubin for various sets of time intervals I0 and I1. In Figure 4, we present
the plots of estimated median curves for cases and controls with respect to four different sets of
time intervals I0 and I1. If bilirubin were not routinely measured for evaluating liver function
clinically, one would recommend its usage for future subjects whose “conventional” scores were
between 0.2 and 0.6. Note that we cannot estimate the medians well for controls beyond 0.6
with this set of data.
Next, we use a more interesting example to illustrate a scenario in which a non-trivial cost is
associated with measuring a new marker. The data set used for our illustration is from a breast
cancer study to evaluate a new genetic marker, “wound-response gene expression signature,” for
predicting patients’ survival (Chang et al., 2005). For each study patient, this gene score was
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derived from the microarray gene expression data. Here, the data set consists of 295 breast cancer
patient files. Each file is composed of a patient’s clinical outcomes (metastasis/death or censoring
time), the gene score, and conventional baseline variables collected at time of surgery, including
age, tumor diameter, number of positive lymph-nodes, tumor grade, vascular invasion, estrogen
receptor status, chemo/hormonal therapy or not, and mastectomy or breast conserving surgery.
The data are available at http://microarray-pubs.stanford.edu/wound_NKI/explore.html, which
were collected at the Netherlands Cancer Institute by van’t Veer et al. (2002) and van de Vijver
et al. (2002). The median follow-up time for those 295 patients is 6.7 years and the range is
0.05 to 18.3 years. The gene score (the so-called Dutch 70) created by the aforementioned Dutch
scientists is different from that proposed by Chang et al. (2005). Here, we are interested in
quantifying the added value from the gene score by Chang et al. over the above conventional
clinical predictors. To this end, we fit the data with two working Cox models, one with gene score
and the other without. The regression coefficient estimates are given in Table 1. Note that the
gene score is statistically significant. The Kaplan-Meier curve of the survival times from these
295 patients is given in Figure 5. First, assume that we are interested in I0  p10,8q (years) and
I1  p0, 10s (years). For our analysis, we used the standard normal kernel and the logp logq as
the ψ function in the nonparametric estimation of the quantiles. Moreover, we used 10-fold cross
validation procedure to choose h. For example, for estimating the medians, the optimal h for
“cases” is 3.25 with respect to the ψ-scale and J is p0.15, 0.85q. Figure 6(a) gives the median curve
(solid curve) and the bands whose boundaries are the 0.25 and 0.75 quantile curves for “cases.”
The x-axis is the score without using gene expression data. Figure 6(b) gives the counterparts for
“controls,” those subjects who would survive beyond 10 years. The density function estimate of
pˆ1 is given in Figure 6(c). The “conventional scores” of the majority of patients in this population
are between 0.2 and 0.75. Note that the median curve is in the positive (negative) side for cases
(controls). The improvement from the gene score, however, is quite modest uniformly over the
conventional score. Since it is relatively expensive to measure the gene score compared with
9
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the routinely obtained clinical marker values, it is not clear from cost-benefit view if we should
measure the gene score for any future patient. In Figure 7, we present plots of estimated median
curves for cases and controls with respect to various sets of time intervals I0 and I1. Again, there
seems no obvious gain from measuring gene score for predicting survival.
4. REMARKS
If a study is designed for evaluating the incremental value from new predictors with respect
to a specific set of time intervals I0 and I1, a global Cox model may not be appropriate for
establishing the risk scores due to the fact that the resulting regression coefficient estimates
reflect an average covariate effect over the entire study time. For this case, we may use, for
example, the logistic regression for modeling the probability of a binary variable with two events
tT P I1u and tT P I0u with predictors and use the technique developed by Uno et al. (2007)
to obtain the risk scores. Then with the same argument in the present paper, nonparametric
function estimates for conditional quantiles can be obtained accordingly. When there is no pre-
specified set of time intervals of interest, one may use the Cox models to obtain unified scores
βˆ1U and γˆ1V first. However, it is important to note that these two scoring systems may not be
comparable since we fit the data with two different models. Therefore, in this paper we convert
the Cox scores to their risk counterparts with respect to a given paired I0 and I1 to evaluate the
incremental values. By considering various sets of I0 and I1 in our analysis, one may identify
when the new markers have practically meaningful added values for prediction. On the other
hand, it is not clear how to utilize the Cox scores directly to perform such subject-level analysis
without discretizing the continuous study follow-up time.
If the conventional scoring system is well-established, one may not need to fit the current
data with the conventional markers. However, for this situation we recommend examining closely
whether the present study population is similar to that from which the conventional score was
constructed.
The graphical method presented here can also be utilized as a quantitative way to assess
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relative merits of two proposed models for fitting survival data. Unlike the lack of fit tests for
model checking or a single summary statistic such as the likelihood ratio, the plots in Figures
4 and 7 with different sets of I0 and I1 provide much more information to help us to choose an
appropriate model with respect to cost-benefit decision making.
It is important to note that the parametric or semi-parametric models used for constructing
the risk scores are simply approximations for the true models. If the “old” model does not fit the
data well, it is difficult if not impossible to determine whether the improvement from the “new”
model is the incremental value from the new predictors or a better model fitting.
5. Appendix
Throughout, unless noted otherwise, we use the notation  to denote equivalence up to opp1q
uniformly in p, À to denote being bounded above up to a universal constant, and 9Fpxq to denote
dFpxq{dx for any function F .
We use Pn and P to denote expectation with respect to the empirical probability measure
of tpXi, δi, Ziq, i  1,    , nu and the probability measure of pX, δ, Zq respectively. Similarly
Gn  n
1
2 pPn  Pq. Let pθ  ppθ11, pθ12q1, pθ1  plog Λˆ1pt1q, log Λˆ1pt2q, log Λˆ1pt3q, log Λˆ1pt4q, pβ1q1, pθ2 
plog Λˆ2pt1q, log Λˆ2pt2q, log Λˆ2pt3q, log Λˆ2pt4q, pγ1q1, where Λˆ1pq and Λˆ2pq are the estimated cumula-
tive hazard functions based on the models with U and with V respectively. Note that p1pU0q 
gppθ11~U01 , pθ11~U02 , pθ11~U03 , pθ11~U04 q and p2pV 0q  gppθ12~V 01 , pθ12~V 02 , pθ12~V 03 , pθ12~V 04 q, where gpx1, x2, x3, x4q 
texppex1q  exppex2qu{texppex1q  exppex2q   exppex3q  exppex4qu and for any vector
x, ~x1  p1, 0, 0, 0, x
1q1, ~x2  p0, 1, 0, 0, x
1q1, ~x3  p0, 0, 1, 0, x
1q1, and ~x4  p0, 0, 0, 1, x1q1.
To establish the consistency of the proposed estimator, we assume that h  Opnνq with
1{2 ¡ ν ¡ 1{5 and pθ converges in probability to a deterministic vector θ0  pθ110, θ120q1. Let
p¯1pU
0q  gpθ110~U
0
1 , θ
1
10
~U02 , θ
1
10
~U03 , θ
1
10
~U04 q, p¯2pV 0q  gpθ120~V 01 , θ120~V 02 , θ120~V 03 , θ120~V 04 q, p¯oi  p¯1pUiq,
p¯ni  p¯2pViq, P0ppq  P pEi  0 | p¯oi  pq, P1ppq  P pEi  1 | p¯oi  pq and ζeppxq denote
the conditional density of ψpp¯niq given p¯oi  p and Ei  e which is assumed to be continuously
differentiable. We assume that ξpxq, the density function of ψpp¯oiq, is continuously differentiable
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with bounded derivatives and bounded away from zero for x P J . We also assume that U and
V are bounded, θ0 is an interior point of a compact set Ω. Furthermore, pθ is a regular estimator
of θ0 with
n1{2ppθ  θ0q  n1{2
 pθ1  θ10pθ2  θ20
ﬀ
 n1{2
n¸
i1
 W1i
W2i

  opp1q. (51)
whereW1i W1pXi, δi, Uiq andW2i W2pXi, δi, Viq for some deterministic functionW1 andW2.
See Uno et al (2007) and Cai et al (2009) for details on establishing the above asymptotic prop-
erties. Furthermore, we note that supt¤t0 |n
1{2t pGptq  Gptqu|  Opp1q (Kalbfleish and Prentice,
2002). It follows that
}pθ  θ0}   sup
t¤t0
| pGptq Gptq|  Oppn1{2q. (52)
It follows that supd,pPrl,rs |P tDˆpZ
0q ¤ d | E0  e, p1pU0q  puP tD¯pZ0q ¤ d | E0  e, p¯1pU0q 
pu|  Oppn
1q and thus |qτeppq  q¯τeppq|  Oppn1q, where q¯τeppq is the τth quantile of D¯pZ0q
given E0  e and p¯1pU0q  p. Thus to establish the consistency of qˆτeppq for p P rl, rs, it suffices
to show that qˆτeppq is uniformly consistent for q¯τeppq.
For the ease of notation, we next establish the consistency of the conditional median qˆ0.5eppq
for the case with e  1 and note that similar arguments can be used for other quantiles. For
any given p, let appq  q¯τeppq p and bppq  9appq for τ  0.5 and e  1, pEippq  ψppoiq  ψppq,
tpappq,pbppqu be the minimizer of
pLpa, b; pq  n1 n¸
i1
pwiE:iKhtpEippqu ψppniq  a bpEippq
and pεppq   pεappqpεbppq


 pappq  appq
htpbppq  bppqu

.
Our objective is to show that supp |pεppq| Ñ 0 in probability as nÑ 8. To this end, we note that
for any given p, pεppq is the minimizer of the objective function pLpε; pq  0, where ε  pεa, εbq1,
pLpε; pq  n1 n¸
i1
pwiE:iKhtpEippqu |ψppniq  Gtε, p;ψppoiq, hu| ,
and Gpε, p; yq  appq   bppqty  ψppqu   εa   εbh1ty  ψppqu.
12
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It suffices to show that pLpε; pq is uniformly consistent for
Lpε; pq  ξtψppquP1ppq
» »
|u tappq   εa   εbvu|Kpvqζ1ppuqdvdu
To this end, we note that |pLpε; pq  Lpε; pq| ¤ E1pε; pq   E2pε; pq   E3pε; pq, where
E1pε; pq  n
1
n¸
i1
| pwi  wi|E:iKhtpEippqu |ψppniq  Gtε, p;ψppoiq, hu|
E2pε; pq 
PnKhtEppquwE: |ψpp¯nq  Gtε, p;ψpp¯oq, hu|  Lpε; pq
E3pε; pq 
PnwE:KhtpEppqu |ψppnq  Gtε, p;ψppoqu|
KhtEppqu |ψpp¯nq  Gtε, p;ψpp¯oqu|

and wi  ∆i{GpXiq, First, following directly from (52), supε;p E1pε; pq  opp1q. Secondly, with
the standard arguments used in Bickel & Rosenblatt (1973), supε;p |E2pε; pq|  Optpnhq
1
2 logpnqu 
opp1q. Lastly, for E3pε; pq, we note that from the inequality that
a1|b1|  a2|b2| ¤ a1|b1  b2|  
|b2||a1  a2| for a1, a2 ¡ 0,
E3pε, pq ¤ PnwE:KhtpEppquψppnq  Gtε, p;ψppoqu  ψpp¯nq   Gtε, p;ψpp¯oqu
 
PnKhtpEppqu KhtEppquwE: |ψpp¯nq  Gtε, p;ψpp¯oqu| 
À Opph
1n1{2q  
» » » »
Khrψtgpu1, u2, u3, u4qu  ψppqsHnpdu1, du2, du3, du4q
whereHnpu1, u2, u3, u4q  PnwE: |ψpp¯nq  Gpε, p;ψpp¯oqq| tIppθ11~U1 ¤ u1, pθ11~U2 ¤ u2, pθ11~U3 ¤ u3, pθ11~U4 ¤
u4qIpθ
1
10
~U1 ¤ u1, θ
1
10
~U2 ¤ u2, θ
1
10
~U3 ¤ u3, θ
1
10
~U4 ¤ u4qu. Furthermore, it follows from integration
by parts,
sup
ε;p
E3pε; pq À h
1 sup |Hnpuq|
À n1{2h1
GnrwE: |ψpp¯nq  Gpε, p;ψpp¯oqq| tIppθ11~U1 ¤ u1, pθ11~U2 ¤ u2, pθ11~U3 ¤ u3, pθ11~U4 ¤ u4q 
Ipθ110~U1 ¤ u1, θ
1
10
~U2 ¤ u2, θ
1
10
~U3 ¤ u3, θ
1
10
~U4 ¤ u4qus
   opp1q. Since the class of functions
twE: |ψpp¯nq  Gtε, p;ψpp¯oqu| Ipθ11~U1  u1 ¤ 0, θ11~U2  u2 ¤ 0, θ11~U3  u3 ¤ 0, θ11~U4  u4 ¤ 0q :
}θ1θ10} ¤ δ, u1, u2, u3, u4, ε, pu, indexed by pθ1, u1, u2, u3, u4, ε, pq, is Donsker, the stochastic pro-
cess GnrwE: |ψpp¯nq  Gpε, p;ψpp¯oqq| Ipθ11~U1u1 ¤ 0, θ11~U2u2 ¤ 0, θ11~U3u3 ¤ 0, θ11~U4u4 ¤ 0qs
13
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is stochastically continuous in θ1. This, coupled with the fact that θˆ1  θ10  opp1q, implies that
sup
GnrwE: |ψpp¯nq  Gpε, p;ψpp¯oqq| tIppθ11~U1 ¤ u1, pθ11~U2 ¤ u2, pθ11~U3 ¤ u3, pθ11~U4 ¤ u4q  Ipθ110~U1 ¤
u1, θ
1
10
~U2 ¤ u2, θ
1
10
~U3 ¤ u3, θ
1
10
~U4 ¤ u4qus
  opp1q. Therefore, E3pε, pq  Oppn1{2h1q  opp1q
uniformly in ε and u. It follows that supε;p |pLpε; pq Lpε; pq|  opp1q. This uniform convergence,
coupled with the fact that 0 is the unique minimizer of Lpε, pq with respect to ε, suggests that
supp |pεppq|  opp1q, which implies the uniform consistency of pappq for appq. This, together with
|qτeppq  q¯τeppq|  Oppn
1q, implies the uniform consistency of qˆτeppq for qτeppq for τ  0.5 and
e  1.
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Table 1. Estimates of regression parameters for Cox’s models with breast cancer data
without gene score with gene score
Est (SE) Est (SE)
Age/10 [yrs] -0.47 (0.17) -0.57 (0.18)
Diameter of tumor [cm] 0.19 (0.11) 0.18 (0.12)
Lymph nodes 0.00 (0.08) -0.01 (0.08)
Grade = 2 vs 1 1.00 (0.35) 0.74 (0.35)
Grade = 3 vs 1 1.11 (0.35) 0.66 (0.37)
Vascular invasion 1-3 vs 0 0.08 (0.37) -0.10 (0.37)
Vascular invasion ¡ 3 vs 0 0.81 (0.62) 0.64 (0.63)
Estrogen Status=Positive -0.39 (0.23) -0.16 (0.24)
Chemo or Hormonal =Yes -0.54 (0.33) -0.49 (0.33)
Mastectomy=Yes 0.13 (0.21) 0.21 (0.22)
Gene score 2.43 (0.67)
18
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Figure 1. Scatterplots of the risk scores with and without bilirubin for subjects whose survival
times are not censored by Year 5
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Figure 2. Estimates of cumulative mortality rates with Mayo PBC survival time data
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Figure 3. Estimated quartiles for the conditional distributions for the differences between the
risk scores with and without bilirubin at Year 5. (a) For subjects who would die by Year 5;
(b) For subjects who would survive beyond Year 5; (c) Estimated density function of the score
without using bilirubin.
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
D^
(a)
D^
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
D^
(b)
D^
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
p^1
R
el
at
ive
 fr
eq
ue
nc
y
(c)
D
en
si
ty
p^1
21
Hosted by The Berkeley Electronic Press
Figure 4. Estimated median curves for the conditional distributions for the differences between
the risk scores with and without bilirubin for various sets of time intervals I0 and I1. (a)
I1  p0, 4s, I0  p4,8q; (b) I1  p0, 4s, I0  p5,8q; (c) I1  p0, 5s, I0  p6,8q; and (d) I1 
p0, 5s, I0  p8,8q.
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Figure 5. Estimates of cumulative mortality rates with breast cancer survival data
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Figure 6. Estimated quartiles for the conditional distributions for the differences between the
risk scores with and without gene score at Year 10. (a) For subjects who would die by Year 10;
(b) For subjects who would survive beyond Year 10; (c) Estimated density function of the score
without using gene score.
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Figure 7. Estimated median curves for the conditional distributions for the differences between
the risk scores with and without gene score for various sets of time intervals I0 and I1. (a)
I1  p0, 3s, I0  p3,8q; (b) I1  p0, 3s, I0  p8,8q; (c) I1  p0, 3s, I0  p4,8q; and (d) I1 
p0, 7s, I0  p8,8q.
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
Case: Die before 3y 
Cotrol: Survive beyond 3y 
(a)
D^
Case: Die before 3y 
Cotrol: Survive beyond 8y 
(b)
0.0 0.2 0.4 0.6 0.8 1.0
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
Case: Die before 3y 
Cotrol: Survive beyond 4y 
(c)
D^
p^1
0.0 0.2 0.4 0.6 0.8 1.0
Case: Die before 7y 
Cotrol: Survive beyond 8y 
(d)
p^1
25
Hosted by The Berkeley Electronic Press
